Shengtai Pharmaceutical Schedules Fiscal Year 2010 Third Quarter Financial Results Conference Call

WEIFANG, China, May 17 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today announced that it issued financial results for the third quarter of fiscal year 2010 (nine months ended March 31, 2010) before the opening of the stock market in USA on Monday, May 17, 2010. Management will conduct a conference call on Tuesday, May 18, 2010 at 8:00 A.M. Eastern Daylight Time to discuss these results. A question and answer session will follow management's presentation.

Mr. Hu Ye (CFO), and Ms. Shenglian Iris Wang (Investor Relations Manager) will be the primary speakers on the call.

To participate, please call the following numbers ten minutes before the call start time:

               Phone Number + 1 (877) 407-8035 (North America)
               Phone Number + 1 (201) 689-8035 (International)

A replay of the call will be available through May 25, 2010, at 11:59 P.M. Eastern Daylight Time. For the replay, please call:

               Phone Number          +1 (877) 660-6853 (North America)
               Phone Number          +1 (201) 612-7415 (International)
               Account Number:       286
               Conference ID Number: 350980

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI), and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a manufacturer and distributor in china of glucose and starch products as pharmaceutical raw materials, other starch products and other glucose products such as corn meals, food and beverage glucose and dextrin. For more information about Shengtai Pharmaceutical, Inc., please visit http://www.shengtaipharmaceutical.com .

Forward Looking Statements

Certain statements in this press release and oral statements made by the Company constitute forward-looking statements concerning the Company's business and products. These statements include, without limitation, statements regarding our ability to prepare the Company for growth, the Company's planned capacity expansion and predictions and guidance relating to the Company's future financial performance. We have based these forward- looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large- scale implementation of the Company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

    For more information, please contact:

     Shengtai Pharmaceutical, Inc.
     Mr. Hu Ye
     Chief Financial Officer
     Tel:   +86-139-1157-3505
     Email: [email protected]

     Shengtai Pharmaceutical, Inc.
     Ms. Shenglian Iris Wang
     Investor Relations Manager
     Tel:   +86-536-6295802
     Email: [email protected]

SOURCE Shengtai Pharmaceutical, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED